Logo
x

Search

Subscribe Now

Cognitive Impairment

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia

Boehringer Ingelheim's BI 425809 Receives the US FDA's Breakthrough Therapy Designation for Cognitive Impairment Associated with S...

  • May 25, 2021
Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study for Patients with Schizophrenia

  • September 15, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.